ASH 2023 | HdxSim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in SCD
Alexandra Power-Hays
• 11 Dec 2023
Alexandra Power-Hays, MD, Cincinnati Children’s, Cincinnati, OH, briefly discusses the development and validation of HdxSim, a clinical decision support tool for model-informed precision dosing (MIPD) of hydroxyurea in children with sickle cell disease (SCD), which has been used to optimize pharmacokinetic (PK)-guided dosing in the ADAPT trial (NCT05662098). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
